SCHEDULE 13G: Royce & Associates LP Discloses 5.81% Passive Stake in OptimizeRx Corp
Beneficial Ownership Report
Investment adviser Royce & Associates LP has reported a 5.81% passive beneficial ownership stake in OptimizeRx Corp, holding 1,069,560 shares of common stock as of December 31, 2024.
Summary
- Royce & Associates LP, an investment adviser based in New York, has filed a Schedule 13G indicating beneficial ownership of OptimizeRx Corp's common stock.
- As of December 31, 2024, Royce & Associates LP beneficially owned 1,069,560 shares of OptimizeRx Corp common stock.
- This ownership represents 5.81% of the total outstanding common stock of OptimizeRx Corp.
- Royce & Associates LP holds sole voting power and sole dispositive power over all 1,069,560 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of OptimizeRx Corp.
- Royce & Associates LP operates as an indirect majority-owned subsidiary of Franklin Resources, Inc. (FRI) and exercises independent investment discretion from FRI affiliates.
Sentiment
Score: 6
Explanation: The filing of a Schedule 13G by a reputable investment firm like Royce & Associates LP, indicating a significant passive stake, is generally viewed as a neutral to mildly positive development, signaling institutional confidence without implying control or immediate strategic changes.
Positives
- The disclosure of a significant stake by an institutional investor like Royce & Associates LP can be viewed as a positive signal, indicating confidence in OptimizeRx Corp's long-term prospects.
- Increased institutional ownership can enhance market visibility and potentially attract further investor interest.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding OptimizeRx Corp's future performance or strategic outlook. It solely reports a passive ownership stake.
Industry Context
This filing indicates an institutional investor's stake in OptimizeRx Corp, a company operating in the healthcare technology sector. Such investments reflect broader investor interest in digital health and pharmaceutical engagement platforms.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence market perception positively.
- Company Management: Awareness of a new significant passive shareholder may influence strategic considerations, though no direct control or influence is implied by a 13G filing.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of the event which required the filing of this statement (beneficial ownership threshold crossed). |
| 01/28/2025 | Date the Schedule 13G was signed and filed by Royce & Associates LP. |
Keywords
OptimizeRx Corp, Royce & Associates LP, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, healthcare technology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.